

Resource Summary Report

Generated by PRECISE-TBI on Sep 19, 2026

MicroVigene

RRID:SCR_002820

Type: Tool

Proper Citation

MicroVigene (RRID:SCR_002820)

Resource Information

URL: <http://www.vigenetech.com/microvigeneV3.0.htm>

Proper Citation: MicroVigene (RRID:SCR_002820)

Description: Automated software program for image analysis based on microarray based image application. Various output styles are available, including image overlay with warping and registration and scattered correlation plot with 2D or 3D spot profile. Outputs can be formatted in text, xml, excel, or custom format.

Resource Type: data processing software, image analysis software, software application, software resource

Keywords: image analysis, array image application, microarray image analysis

Availability: Free, Freely available, Available for download

Resource Name: MicroVigene

Resource ID: SCR_002820

Alternate IDs: OMICS_00845

Record Creation Time: 20220129T080215+0000

Record Last Update: 20260912T200053+0000

Ratings and Alerts

No rating or validation information has been found for MicroVigene.

No alerts have been found for MicroVigene.

Data and Source Information

Usage and Citation Metrics

We found 107 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Klose AM, et al. (2026) Dual-Scale StaphAIR: Predictive Modeling for the Diagnosis of *S. aureus* Infection via Simultaneous Detection and Quantification of Cytokines and Antibodies. *Analytical chemistry*, 98(21), 15599.

He C, et al. (2026) A Brand-New Drainage Fluid Predictor, ICAM-1 for Implant Loss After the Immediate Reconstruction of Breast. *Breast cancer (Dove Medical Press)*, 18, 585358.

Ali MM, et al. (2026) The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal Melanoma. *Cancers*, 18(12).

McBean B, et al. (2026) Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibition. *NPJ breast cancer*, 12(1).

Zhang T, et al. (2025) CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling. *Research square*.

Ning B, et al. (2025) Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer. *Scientific reports*, 15(1), 3211.

Raj-Kumar PK, et al. (2025) Proteogenomic characterization of invasive breast tumors in young women. *NPJ breast cancer*, 11(1), 94.

Bateman NW, et al. (2024) Proteogenomic analysis of enriched HGSOc tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. *NPJ precision oncology*, 8(1), 68.

Chattopadhyay C, et al. (2024) Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. *British journal of cancer*, 131(11), 1846.

Elias AD, et al. (2024) Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer. *NPJ breast cancer*, 10(1), 88.

Dickinson SE, et al. (2024) Inhibition of UV-Induced Stress Signaling and Inflammatory Responses in SKH-1 Mouse Skin by Topical Small-Molecule PD-L1 Blockade. *JID innovations : skin science from molecules to population health*, 4(2), 100255.

Bylicky MA, et al. (2024) Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention. *Molecular cancer therapeutics*, 23(4), 577.

Escobar Marcillo DI, et al. (2024) The dual nature of DNA damage response in obesity and bariatric surgery-induced weight loss. *Cell death & disease*, 15(9), 664.

Hunt AL, et al. (2024) Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling. *Clinical proteomics*, 21(1), 4.

Conlon NT, et al. (2024) Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo. *Translational oncology*, 49, 102073.

Nam DE, et al. (2024) Activated Gab1 drives hepatocyte proliferation and anti-apoptosis in liver fibrosis via potential involvement of the HGF/c-Met signaling axis. *PloS one*, 19(6), e0306345.

Sharma A, et al. (2024) Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes. *Oncogenesis*, 13(1), 22.

Stewart CA, et al. (2024) YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(20), 4743.

Jiang VC, et al. (2023) Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. *The Journal of clinical investigation*, 133(3).

Abu-Khalaf MM, et al. (2023) AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. *NPJ precision oncology*, 7(1), 18.